8-K: Verastem Oncology Highlights Strong Clinical Data for Pancreatic Cancer Drug and Advances Novel KRAS Inhibitor

Verastem Oncology presented encouraging clinical data from its RAMP 205 trial for metastatic pancreatic cancer and provided updates on its novel KRAS G12D inhibitor, VS-7375, following the recent FDA approval of AVMAPKI FAKZYNJA CO-PACK.

Summary

• Verastem Oncology recently received FDA approval on May 8, 2025, for AVMAPKI FAKZYNJA CO-PACK as the first and only treatment for KRAS-mutated recurrent Low-Grade Serous Ovarian Cancer (LGSOC), demonstrating a 44% Overall Response Rate (ORR) and a median Duration of Response (mDOR) of 3.3 to 31.1 months.
• The RAMP 205 Phase 1/2 trial for newly diagnosed metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) showed an 83.3% unconfirmed ORR (10/12 patients) and 66.7% confirmed ORR (8/12 patients) in Dose Level 1, with tumor shrinkage observed in all 12 patients.
• Dose Level 1 was selected as the Recommended Phase 2 Dose (RP2D) for the avutometinib plus defactinib combination with gemcitabine and nab-paclitaxel, with patients poised to exceed historical median Progression-Free Survival (mPFS) estimates of 5.5-5.6 months.
• VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, demonstrated superior preclinical efficacy compared to other KRAS ON inhibitors and achieved complete responses in a colorectal cancer model when combined with cetuximab.
• Initial Phase 1 data from China for GFH375 (VS-7375) showed a 52% ORR in pancreatic cancer and 42% ORR in non-small cell lung cancer (NSCLC) patients with KRAS G12D mutations, with a manageable safety profile and once-daily dosing.
• Verastem initiated its US Phase 1/2a study for VS-7375 in May 2025, with planned expansion cohorts in PDAC, NSCLC, and a combination with cetuximab in colorectal cancer (CRC).

Sentiment

Score: 9

Explanation: The document conveys a highly positive sentiment, driven by the recent FDA approval, exceptionally strong preliminary clinical efficacy data for RAMP 205 in pancreatic cancer, and promising preclinical and early clinical data for the novel KRAS G12D inhibitor, VS-7375. The company outlines clear next steps for advancing these programs, indicating strong progress and future potential.

Positives

• FDA approval of AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent LGSOC marks a significant milestone and provides a novel treatment option.
• The RAMP 205 trial for mPDAC demonstrated an impressive 83.3% unconfirmed ORR and 66.7% confirmed ORR in Dose Level 1, significantly higher than historical chemotherapy benchmarks.
• Tumor shrinkage was observed in all 12 patients in Dose Level 1 of the RAMP 205 trial, indicating broad efficacy.
• The safety profile of the RAMP 205 combination was generally manageable, allowing most patients to remain on treatment.
• VS-7375 shows a differentiated preclinical profile as an ON/OFF KRAS G12D inhibitor, suggesting potentially more complete and durable inhibition.
• Early clinical data for VS-7375 (GFH375) from China demonstrated encouraging ORRs of 52% in PDAC and 42% in NSCLC, along with a tolerable safety profile and convenient once-daily dosing.
• Verastem is strategically pursuing high unmet need areas like pancreatic cancer and KRAS G12D-mutated cancers, which represent significant market opportunities.

Negatives

• The RAMP 205 trial's Dose Level 1 showed some increased rates of nausea, diarrhea, constipation, febrile neutropenia, and anemia compared to what is expected with gemcitabine/nab-paclitaxel alone, though generally manageable.
• The efficacy data for RAMP 205 is still preliminary, based on a small cohort (n=12) for Dose Level 1, and requires further confirmation in larger studies.
• The forward-looking statements highlight numerous inherent risks in drug development, including uncertainties in clinical trial outcomes, regulatory approvals, commercial success, and competition.

Risks

• The success in the development and potential commercialization of product candidates, including avutometinib in combination with other compounds, is uncertain.
• There are inherent uncertainties in research and development, such as negative or unexpected results of clinical trials.
• The occurrence or timing of applications for product candidates that may be filed with regulatory authorities in any jurisdictions is uncertain.
• Whether and when regulatory authorities may approve applications for product candidates, and if approved, whether they will be commercially successful, is a risk.
• The ability to obtain, maintain, and enforce patent and other intellectual property protection for product candidates is not guaranteed.
• Decisions by regulatory authorities regarding trial design, labeling, and other matters could affect the timing, availability, or commercial potential of product candidates.
• Whether preclinical testing and preliminary or interim data from clinical trials will be predictive of the results or success of ongoing or later clinical trials is uncertain.
• The timing, scope, and rate of reimbursement for product candidates is uncertain.
• Market opportunities of drug candidates are based on internal and third-party estimates which may prove to be incorrect.
• Third-party payors (including government agencies) may not reimburse for the products.
• There may be competitive developments affecting product candidates, resulting in others developing or commercializing products before or more successfully.
• Data may not be available when expected, and enrollment of clinical trials may take longer than expected, which may delay development programs.
• Risks associated with preliminary and interim data, which may not be representative of more mature data, including with respect to interim duration of therapy data.
• Product candidates may cause adverse safety events and/or unexpected concerns may arise from additional data or analysis, or result in unmanageable safety profiles.
• The company may be unable to successfully validate, develop, and obtain regulatory approval for companion diagnostic tests for product candidates.
• Product candidates may experience manufacturing or supply interruptions or failures.
• Any third-party contract research organizations, contract manufacturing organizations, clinical sites, or contractors may fail to fully perform.
• The company faces substantial competition, which may result in reduced market share or market potential for product candidates.
• The development and commercialization of product candidates will take longer or cost more than planned.
• The company may not have sufficient cash to fund contemplated operations, including product development programs.
• The company may not attract and retain high-quality personnel.
• The company or Chugai Pharmaceutical Co., Ltd. may fail to fully perform under the avutometinib license agreement.
• Total addressable and target markets for product candidates might be smaller than presently estimated.
• The company or Secura Bio, Inc. may fail to fully perform under the asset purchase agreement, including in relation to milestone payments.
• The company may not see a return on investment on payments made pursuant to the collaboration and option agreement with GenFleet, or GenFleet may fail to fully perform.
• The company may not be able to establish new or expand on existing collaborations or partnerships on favorable terms, or at all.
• The company may be unable to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity, debt financing or otherwise.
• The company may not pursue or submit regulatory filings for product candidates.
• Product candidates may not receive regulatory approval, become commercially successful products, or result in new treatment options being offered to patients.

Future Outlook

Verastem plans to expand enrollment for the RAMP 205 trial to 29 patients and aims to launch a pivotal Phase 3 study in first-line metastatic pancreatic ductal adenocarcinoma (PDAC) in 2026. For VS-7375, the company is initiating enrollment in its US Phase 1/2a trial with expansion cohorts planned for PDAC, NSCLC, and a combination with cetuximab in CRC, with potential for additional combinations and tumor types including newly diagnosed PDAC and NSCLC, and recurrent endometrial cancer.

Management Comments

• Daniel Paterson, President & CEO, emphasized Verastem Oncology's multi-faceted approach to improving outcomes in RAS/MAPK pathway driven cancers by pursuing unexplored avenues with novel small molecule drugs.
• Vincent Picozzi, M.D., highlighted Pancreatic Ductal Adenocarcinoma (PDAC) as an area of high unmet need due to its low 5-year relative survival rate and high prevalence of KRAS mutations.
• Jon Pachter, Ph.D., CSO, stated that VS-7375 is a dual inhibitor of ON (GTP) and OFF (GDP) states of KRAS G12D, which may be ideal for maintaining inhibition around the clock for maximum efficacy.
• David Hong, M.D., noted that KRAS G12D is the most frequent KRAS mutation in human cancers, especially prevalent in pancreatic and colorectal cancers, and has historically been challenging to target.
• John Hayslip, M.D., CMO, expressed that the RAMP 205 results present an opportunity for avutometinib plus defactinib with SOC chemo to reshape expectations in advanced pancreatic cancer, with most patients achieving objective responses.
• Management believes VS-7375 has the potential to meet a significant unmet need in solid tumor cancers, targeting 61,000 metastatic KRAS G12D patients diagnosed annually.

Industry Context

The oncology industry is increasingly focusing on targeted therapies for specific genetic mutations, such as KRAS, which is prevalent in many difficult-to-treat cancers like pancreatic, lung, and colorectal cancers. Pancreatic cancer, in particular, remains an area of high unmet medical need with very low 5-year survival rates. Verastem's dual approach with a recently FDA-approved combination for LGSOC and promising clinical data for a novel KRAS G12D inhibitor positions it within the forefront of precision oncology, addressing critical pathways like RAS/MAPK.

Comparison to Industry Standards

• The RAMP 205 trial's Dose Level 1 demonstrated an 83.3% unconfirmed ORR and 66.7% confirmed ORR in newly diagnosed metastatic PDAC. This compares favorably to standard first-line therapies like FOLFIRINOX (median ORR = 31.6%) and Gemcitabine/nab-paclitaxel (median ORR = 23-36.2%).
• Patients in RAMP 205 Dose Level 1 are 'poised to exceed historical estimates of mPFS' (median Progression-Free Survival) for Gemcitabine/nab-paclitaxel, which are typically 5.5 months (MPACT study, N=421) and 5.6 months (NAPOLI 3 study, N=387).
• VS-7375's preclinical data suggests improved KRAS G12D selectivity and potency compared to other KRAS G12D inhibitors like MRTX1133 and RMC-9805, and it demonstrated more efficacy than KRAS ON inhibitors in reducing tumor growth in KRAS G12D models.
• The initial Phase 1 data for VS-7375 (GFH375) from China showed a 52% ORR in PDAC and 42% ORR in NSCLC, which are encouraging response rates for heavily pre-treated patients in these difficult-to-treat KRAS G12D mutant populations.

Legal Proceedings

• The company lists 'the scope, timing, and outcome of any legal proceedings' as a general risk factor, but no specific legal proceedings are detailed in the document.

Stakeholder Impact

• **Shareholders/Investors**: The positive clinical data and FDA approval could lead to increased investor confidence and potential share price appreciation. The outlined future development plans provide a clear roadmap for value creation.
• **Patients**: The FDA approval of AVMAPKI FAKZYNJA CO-PACK offers a new treatment option for KRAS-mutated recurrent LGSOC. The promising RAMP 205 data suggests a potentially more efficacious treatment for metastatic pancreatic cancer, a disease with high unmet need, offering hope for improved outcomes.
• **Healthcare Providers**: The new FDA-approved drug and the potential future therapies could provide additional tools for oncologists to treat challenging cancers, particularly those driven by RAS/MAPK pathway mutations.
• **Employees**: Continued positive clinical development and potential commercial success could lead to job security and growth opportunities within the company.
• **Regulatory Authorities**: The company's ongoing clinical trials and future regulatory submissions will require continued engagement and review by bodies like the FDA.

Next Steps

• Expand enrollment for the RAMP 205 Phase 1/2 trial to 29 patients in the dose expansion cohort.
• Plan to launch a pivotal Phase 3 study in first-line metastatic PDAC in 2026.
• Conduct further regulatory interactions to align on plans for the PDAC program.
• Continue to evaluate combination strategies with current pipeline and external assets to improve outcomes in mPDAC.
• Initiate enrollment for the US Phase 1/2a study of VS-7375 (VS-7375-101) with an efficacious dose level (400 mg QD).
• Initiate planned expansion cohorts for VS-7375 in 2L+ PDAC and 2L+ NSCLC.
• Initiate a planned expansion cohort for VS-7375 in combination with cetuximab in 2L+ CRC.
• Evaluate VS-7375 in additional combinations and tumor types, including newly diagnosed PDAC, newly diagnosed NSCLC, and recurrent endometrial cancer.

Key Dates

Recommendation

Keywords

Verastem Oncology, Avutometinib, Defactinib, VS-7375, KRAS G12D inhibitor, Pancreatic Cancer, Low-Grade Serous Ovarian Cancer, RAS/MAPK pathway, Oncology, Clinical Trials, FDA Approval, Biotechnology, Pharmaceuticals, Cancer Treatment, Targeted Therapy